Home › Adrenocortical Carcinoma › New York
Adrenocortical Carcinoma clinical trials in New York
3 studies for Adrenocortical Carcinoma are looking for participants at sites in New York.
Cities in New York
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Memorial Sloan Kettering Cancer Center, New York
- and 1 more
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 18, 2026 · NCT06900595A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
- Columbia University, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07189403Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
- Memorial Sloan Kettering Suffolk-Commack, Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06066333From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.